Adjuvants for COVID-19 Vaccines
In recent decades, the improvement of traditional vaccines has meant that we have moved from inactivated whole virus vaccines, which provoke a moderate immune response but notable adverse effects, to much more processed vaccines such as protein subunit vaccines, which despite being less immunogenic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/5/902 |
| _version_ | 1797598180530978816 |
|---|---|
| author | Javier Castrodeza-Sanz Iván Sanz-Muñoz Jose M. Eiros |
| author_facet | Javier Castrodeza-Sanz Iván Sanz-Muñoz Jose M. Eiros |
| author_sort | Javier Castrodeza-Sanz |
| collection | DOAJ |
| description | In recent decades, the improvement of traditional vaccines has meant that we have moved from inactivated whole virus vaccines, which provoke a moderate immune response but notable adverse effects, to much more processed vaccines such as protein subunit vaccines, which despite being less immunogenic have better tolerability profiles. This reduction in immunogenicity is detrimental to the prevention of people at risk. For this reason, adjuvants are a good solution to improve the immunogenicity of this type of vaccine, with much better tolerability profiles and a low prevalence of side effects. During the COVID-19 pandemic, vaccination focused on mRNA-type and viral vector vaccines. However, during the years 2022 and 2023, the first protein-based vaccines began to be approved. Adjuvanted vaccines are capable of inducing potent responses, not only humoral but also cellular, in populations whose immune systems are weak or do not respond properly, such as the elderly. Therefore, this type of vaccine should complete the portfolio of existing vaccines, and could help to complete vaccination against COVID-19 worldwide now and over the coming years. In this review we analyze the advantages and disadvantages of adjuvants, as well as their use in current and future vaccines against COVID-19. |
| first_indexed | 2024-03-11T03:15:44Z |
| format | Article |
| id | doaj.art-bbc50547a0124eb09be243ffa1f01c1e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T03:15:44Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-bbc50547a0124eb09be243ffa1f01c1e2023-11-18T03:35:29ZengMDPI AGVaccines2076-393X2023-04-0111590210.3390/vaccines11050902Adjuvants for COVID-19 VaccinesJavier Castrodeza-Sanz0Iván Sanz-Muñoz1Jose M. Eiros2National Influenza Centre, 47005 Valladolid, SpainNational Influenza Centre, 47005 Valladolid, SpainNational Influenza Centre, 47005 Valladolid, SpainIn recent decades, the improvement of traditional vaccines has meant that we have moved from inactivated whole virus vaccines, which provoke a moderate immune response but notable adverse effects, to much more processed vaccines such as protein subunit vaccines, which despite being less immunogenic have better tolerability profiles. This reduction in immunogenicity is detrimental to the prevention of people at risk. For this reason, adjuvants are a good solution to improve the immunogenicity of this type of vaccine, with much better tolerability profiles and a low prevalence of side effects. During the COVID-19 pandemic, vaccination focused on mRNA-type and viral vector vaccines. However, during the years 2022 and 2023, the first protein-based vaccines began to be approved. Adjuvanted vaccines are capable of inducing potent responses, not only humoral but also cellular, in populations whose immune systems are weak or do not respond properly, such as the elderly. Therefore, this type of vaccine should complete the portfolio of existing vaccines, and could help to complete vaccination against COVID-19 worldwide now and over the coming years. In this review we analyze the advantages and disadvantages of adjuvants, as well as their use in current and future vaccines against COVID-19.https://www.mdpi.com/2076-393X/11/5/902vaccinesadjuvantsCOVID-19immune response |
| spellingShingle | Javier Castrodeza-Sanz Iván Sanz-Muñoz Jose M. Eiros Adjuvants for COVID-19 Vaccines Vaccines vaccines adjuvants COVID-19 immune response |
| title | Adjuvants for COVID-19 Vaccines |
| title_full | Adjuvants for COVID-19 Vaccines |
| title_fullStr | Adjuvants for COVID-19 Vaccines |
| title_full_unstemmed | Adjuvants for COVID-19 Vaccines |
| title_short | Adjuvants for COVID-19 Vaccines |
| title_sort | adjuvants for covid 19 vaccines |
| topic | vaccines adjuvants COVID-19 immune response |
| url | https://www.mdpi.com/2076-393X/11/5/902 |
| work_keys_str_mv | AT javiercastrodezasanz adjuvantsforcovid19vaccines AT ivansanzmunoz adjuvantsforcovid19vaccines AT josemeiros adjuvantsforcovid19vaccines |